text: <unk>  is an tyrosine kinase inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.   Common adverse reactions include diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot syndrome, weight decreased, vomiting, asthenia, and constipation.
option_0: Axitinib
option_1: Ceritinib
option_2: Sunitinib
option_3: Afatinib
option_4: Erdafitinib
option_5: Dacomitinib
option_6: Neratinib
option_7: Baricitinib